New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
06:31 EDTALXNAlexion recommends rejection of mini-tender offer by TRC Capital
Alexion has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation to purchase up to 1.5M shares, or approximately 0.77%, of the outstanding Alexion common stock at a price of $90.50 per share. TRC's offer price represents approximately a 5.06% discount to the closing price of Alexion common stock on February 5. Alexion does not endorse TRC's offer and recommends that shareholders reject the offer and do not tender their shares. Alexion urges shareholders considering TRC's offer to obtain current market quotations for their shares, review the conditions to the offer, consult with their broker or financial adviser and exercise caution with respect to TRC's offer. Alexion is not associated in any way with TRC, its mini-tender offer or the offer documentation.
News For ALXN From The Last 14 Days
Check below for free stories on ALXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:34 EDTALXNAlexion names Hallal COO, Carmichael Chief Human Resources Officer
Subscribe for More Information
07:33 EDTALXNAlexion names Hallal COO, Carmichael Chief Human Resources Officer
September 14, 2014
17:44 EDTALXNAlexion presents data on pediatric HPP patients treated with asfotase alfa
Alexion Pharmaceuticals announced that researchers presented new data from an integrated analysis of survival from two open-label, Phase 2 studies of asfotase alfa in pediatric patients with hypophosphatasia, HPP, compared with data from a retrospective natural history study of untreated historical control patients matched for age and disease severity. In this analysis, survival in patients with HPP at high risk of death who were treated with asfotase alfa for up to five years was significantly improved compared with untreated historical control patients.These late-breaking results were presented at the American Society for Bone and Mineral Research, ASBMR, 2014 Annual Meeting in Houston, where researchers also presented new data from the ongoing open-label extension phases of two Phase 2 clinical studies in which sustained gains in physical function and reductions in disability and pain were observed in pediatric patients receiving asfotase alfa treatment for up to three years.
September 12, 2014
07:14 EDTALXNAmerican Society for Bone & Mineral Research holds annual meeting
Subscribe for More Information
September 8, 2014
06:31 EDTALXNAlexion announces asfotase alfa granted orphan drug designation in Japan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use